The closing price of Milestone Scientific Inc. (AMEX: MLSS) was $0.62 for the day, down -1.03% from the previous closing price of $0.63. In other words, the price has decreased by -$0.0065 from its previous closing price. On the day, 139757 shares were traded.
Ratios:
Our analysis of MLSS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 3.04. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
On November 16, 2018, Maxim Group reiterated its Buy rating and also upped its target price recommendation from $3 to $1.50.
Maxim Group reiterated its Buy rating for the stock on December 23, 2016, while the target price for the stock was revised from $5 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLSS now has a Market Capitalization of 47.96M and an Enterprise Value of 43.76M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.80 while its Price-to-Book (P/B) ratio in mrq is 6.09. Its current Enterprise Value per Revenue stands at 4.46 whereas that against EBITDA is -6.26.
Stock Price History:
The Beta on a monthly basis for MLSS is 0.97, which has changed by -30.77% over the last 52 weeks, in comparison to a change of 27.86% over the same period for the S&P500. Over the past 52 weeks, MLSS has reached a high of $1.35, while it has fallen to a 52-week low of $0.52. The 50-Day Moving Average of the stock is 0.6602, while the 200-Day Moving Average is calculated to be 0.8499.
Shares Statistics:
MLSS traded an average of 88.01K shares per day over the past three months and 91.37k shares per day over the past ten days. A total of 69.27M shares are outstanding, with a floating share count of 45.06M. Insiders hold about 40.41% of the company’s shares, while institutions hold 5.44% stake in the company. Shares short for MLSS as of Mar 15, 2024 were 425.28k with a Short Ratio of 4.83, compared to 499.95k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.56% and a Short% of Float of 0.71%.
Earnings Estimates
The firm’s stock currently is rated by 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.03. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $2.76M to a low estimate of $2.76M. As of the current estimate, Milestone Scientific Inc.’s year-ago sales were $2.22M, an estimated increase of 24.50% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $3.19M, an increase of 42.30% over than the figure of $24.50% in the same quarter last year. There is a high estimate of $3.19M for the next quarter, whereas the lowest estimate is $3.19M.
A total of 1 analysts have provided revenue estimates for MLSS’s current fiscal year. The highest revenue estimate was $10.57M, while the lowest revenue estimate was $10.57M, resulting in an average revenue estimate of $10.57M. In the same quarter a year ago, actual revenue was $8.81M, up 20.00% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $12.84M in the next fiscal year. The high estimate is $12.84M and the low estimate is $12.84M. The average revenue growth estimate for next year is up 21.50% from the average revenue estimate for this year.
